Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 13, 2005. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility under the GlaxoSmithKline Performance Share Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share transaction notifications.
Material Changes
There are no material changes to financial performance reported. The filing details an increase in Ordinary Share ADR holdings for specific individuals following the re-investment of dividends paid on October 6, 2005. The transaction price was $51.51 per ADR.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, risks, contingencies, or unusual items. It is a compliance notification regarding Disclosure Rules 3.1.4R(1)(a) and 3.1.4R(1)(b).
Key Facts for Investors to Verify
- Transaction Date: October 13, 2005.
- Transaction Type: Increase in ADR interests via dividend re-investment.
- Price per ADR: $51.51.
- Dividend Date: October 6, 2005.
- Individuals Notified: Dr. W. Calhoun (35.127 ADRs), Dr. J. P. Garnier (245.956 ADRs), and Mr. D. Phelan (52.704 ADRs).